Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth

Eli Lilly (LLY) is poised to report Q2 2025 earnings on August 7, with Wall Street anticipating robust growth: $5.61 EPS (+43.1% YoY) and $14.75 billion revenue (+30.5% YoY). Despite a recent 1.46% downward revision in the consensus EPS estimate, a positive Zacks Earnings ESP of +0.18% and a Zacks Rank #3 indicate a high likelihood of an earnings beat, which could positively impact the stock. Separately, Pfizer (PFE) is also projected to exceed its consensus EPS estimate for the same quarter, despite an expected year-over-year earnings decline.

Analysis

Eli Lilly (LLY) is approaching its Q2 2025 earnings report with high expectations, as consensus estimates project significant year-over-year growth in both revenue (+30.5% to $14.75 billion) and earnings per share (+43.1% to $5.61). Despite this strong growth outlook, analyst sentiment has moderately cooled, reflected by a 1.46% downward revision of the consensus EPS estimate over the last 30 days. Nonetheless, quantitative indicators suggest a high probability of an earnings beat; the company's Zacks Earnings ESP is a positive +0.18%, which, combined with a Zacks Rank of #3 (Hold), historically indicates a nearly 70% chance of surpassing the consensus EPS. This positive quantitative signal is tempered by the company's recent performance history, which includes an EPS miss of -5.11% in the last reported quarter and beats in only two of the last four quarters. Therefore, while a headline beat is the most likely outcome, the magnitude of the beat and, more importantly, management's forward-looking guidance on the earnings call will be critical determinants for the stock's sustained price movement.

Key Decisions for Investors

• Given the positive Earnings ESP of +0.18% and robust growth forecasts, investors may consider positioning for a potential earnings beat, but should remain aware that a beat is already partially priced in by the market.
• The recent downward revision in consensus EPS and a mixed surprise history, including a notable miss last quarter, warrant a degree of caution; traders should monitor for any weakness in management's guidance as a potential catalyst for a post-earnings sell-off.
• Focus should be placed on the qualitative aspects of the August 7th report, specifically management's commentary on business conditions and future outlook, as these factors will likely have a more lasting impact on the stock's valuation than the initial reaction to the headline numbers.